Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have been given a consensus recommendation of “Buy” by the eleven research firms that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $49.75.

DCPH has been the subject of several recent analyst reports. Leerink Swann reaffirmed a “positive” rating and set a $29.00 price objective (up from $20.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 14th. Cantor Fitzgerald lifted their target price on Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 16th. Piper Jaffray Companies lifted their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Finally, ValuEngine downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th.

In related news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $36.42, for a total value of $12,747,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Douglas Taylor sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $36.26, for a total transaction of $271,950.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at $271,950. The disclosure for this sale can be found here. Insiders sold 539,534 shares of company stock valued at $20,465,526 over the last 90 days. 7.02% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can bought a new position in Deciphera Pharmaceuticals in the second quarter worth about $28,000. BNP Paribas Arbitrage SA grew its stake in shares of Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after acquiring an additional 1,831 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth about $64,000. JPMorgan Chase & Co. grew its stake in shares of Deciphera Pharmaceuticals by 89.2% during the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after acquiring an additional 1,913 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Deciphera Pharmaceuticals by 214.8% during the second quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after acquiring an additional 5,366 shares during the last quarter. Institutional investors and hedge funds own 45.68% of the company’s stock.

DCPH traded up $1.30 during trading on Thursday, reaching $36.86. 18,219 shares of the company traded hands, compared to its average volume of 386,548. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals has a 12-month low of $18.55 and a 12-month high of $42.99. The firm has a fifty day simple moving average of $30.99 and a 200 day simple moving average of $25.60. The company has a market cap of $1.79 billion, a P/E ratio of -13.04 and a beta of 1.92.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.56. The company had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $20.00 million. As a group, sell-side analysts expect that Deciphera Pharmaceuticals will post -4.21 earnings per share for the current fiscal year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: How the Consumer Price Index (CPI) is calculated?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.